Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial

Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19.

Authors

Ikaro Breder¹, Vaneza Lira W Wolf¹, Alexandre A S Soares¹, Luiz Sergio F de Carvalho¹, Sheila T Kimura-Medorima¹, Riobaldo M Cintra¹, Joaquim Barreto¹, Daniel B Munhoz¹, Jessica S Cunha², Isabella Bonilha¹, Otavio R Coelho-Filho³, Thiago Quinaglia¹, Wilson Nadruz³, Gil Guerra-Junior⁴, Elza Muscelli³, Andrei C Sposito⁵; ADDENDA-BHS2 Trial Investigators

Affiliations

¹ Laboratory of Vascular Biology and Atherosclerosis. University of Campinas, Campinas, SP, Brazil.
² College of Nursing, University of Campinas, Campinas, SP, Brazil.
³ Department of Internal Medicine, University of Campinas, SP, Brazil.
⁴ Growth and Development Lab, Centre for Investigation in Paediatrics, University of Campinas, Campinas, SP, Brazil.
⁵ Laboratory of Vascular Biology and Atherosclerosis. University of Campinas, Campinas, SP, Brazil; Department of Internal Medicine, University of Campinas, SP, Brazil. Electronic address: andreisposito@gmail.com.

PMID: 34808345
DOI: 10.1016/j.diabet.2021.101304

No abstract available

Keywords: Adipokines; Body fat composition; Inflammation; Obesity; Sodium-glucose transporter 2.

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Adiponectin
Adiposity
Benzhydryl Compounds / therapeutic use
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucosides / therapeutic use
Humans
Obesity

Substances

Adiponectin
Benzhydryl Compounds
Glucosides
dapagliflozin